The Phase III BROOKLYN trial saw HeFH patients randomly assigned in a 2:1 ratio to receive either obicetrapib or a placebo ...
In addition, reductions in triglycerides and atherogenic proteins such as apolipoprotein B (ApoB), lipoprotein (a) [Lp(a)], and apolipoprotein C-III (ApoC-III) were observed. Regarding safety ...
Scott M. Grundy, MD, PhD. Dr Grundy is director of the Center for Human Nutrition, chairman of the Department of Clinical Nutrition, and professor of internal medicine at the University of Texas ...
This study endeavored to assess the lipid profile and atherogenic lipid indexes in children with transfusion-dependent thalassemia (TDT) and to compare them with matched healthy children. The study ...
The study, say investigators, suggests that reducing LDL cholesterol with lipid-lowering therapies will not be enough to offset the risk associated with atherogenic Lp(a). “You can control LDL ...
L-C has been shown to have benefits for CVD but is also believed to be associated with pro-atherogenic mechanisms. We have previously shown that L-C does not cause plaque progression (no effect) in ...